The value of combining the radiosensitizer misonidazole with cyclophosphamide in treating the murine Lewis lung tumor.
Cyclophosphamide and the radiosensitizer misonidazole were combined to determine if any therapeutic benefit could be demonstrated with this combination in treating the murine Lewis lung tumor. The results of our in vivo studies indicated that when various dosage schedules of misonidazole were combined with cyclophosphamide, the tumor effect was greater than when cyclophosphamide was administered alone. However, the increased effect of the two drug combination was determined to be no greater than an additive effect of cyclophosphamide tumor cell toxicity plus misonidazole cytotoxicity. Furthermore, host toxicity was enhanced when the two drugs were combined as indicated by the LD50 assay. We conclude that combining cyclophosphamide with misonidazole offers little if any therapeutic advantage since the increase in host toxicity appears to be as greater as the increase in tumor cell killing.
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D007700:Kinetics; D008175:Lung Neoplasms / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008920:Misonidazole / Q000378:metabolism / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009593:Nitroimidazoles / Q000627:therapeutic use*; D013997:Time Factors
D009593:Nitroimidazoles; D008920:Misonidazole; D003520:Cyclophosphamide